Heather Ledbetter Prichard - 24 May 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Operating Officer
Signature
/s/ Heather Ledbetter Prichard by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
24 May 2023
Net transactions value
-$157
Form type
4
Filing time
26 May 2023, 17:05:09 UTC
Previous filing
13 Dec 2022
Next filing
12 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Options Exercise $16,409 +13,789 +150% $1.19 22,978 24 May 2023 Direct
transaction HUMA Common Stock Sale $57,086 -13,789 -60% $4.14 9,189 24 May 2023 Direct F1
transaction HUMA Common Stock Options Exercise $77,338 +64,990 +707% $1.19 74,179 25 May 2023 Direct
transaction HUMA Common Stock Sale $36,818 -9,613 -13% $3.83 64,566 25 May 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Options Exercise $0 -13,789 -18% $0.000000 64,990 24 May 2023 Common Stock 13,789 $1.19 Direct
transaction HUMA Stock Options (right to buy) Options Exercise $0 -64,990 -100% $0.000000* 0 25 May 2023 Common Stock 64,990 $1.19 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.14 to $4.16. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.82 to $3.89. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.